What is MapLight Therapeutics, Inc.'s (MPLT) StockRank?

MoatMap's StockRank for MapLight Therapeutics, Inc. (MPLT) is 21/100, with a Sell signal. This is a composite score combining Quality (34), Value (31), and Momentum (41) factor ranks across MoatMap's universe of 25,000+ stocks.

Does MapLight Therapeutics, Inc. have an economic moat?

MapLight Therapeutics, Inc. (MPLT) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the financial characteristics of a moated business.

Is MapLight Therapeutics, Inc. a buy, hold, or sell?

MoatMap's current signal for MapLight Therapeutics, Inc. (MPLT) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.

What sector is MapLight Therapeutics, Inc. in?

MapLight Therapeutics, Inc. (MPLT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).

Company Deep Dive

Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.

Request Deep Dive(50 Feathers)

MPLT

SellSinker

MapLight Therapeutics, Inc. · Healthcare · United States · $584M · Avg Vol: $10M/d

StockRank

Get insider-trade alerts

P/E (TTM)

—

ROE

-111.5%

D/E

0.0x

Dividend %

—

COMPANY DESCRIPTION

MapLight Therapeutics, Inc. is a clinical-stage biopharmaceutical company committed to developing novel therapeutics for central nervous system (CNS) disorders, with a primary focus on psychiatric and neurological conditions. The company employs a proprietary drug discovery platform to identify and advance differentiated small molecule candidates that target specific neuroreceptor pathways, aiming to address significant unmet medical needs with potential first-in-class treatments.

FINANCIAL SUMMARY (USD)

Year	2022	2023	2024	2025	CAGR	TTM	2027E	Fwd CAGR
Revenue	—	—	—	0	—	—	16.7M	—
EPS	—	—	-2.96	-18.56	—	-19.96	-3.68	—
Shares	—	—	—	44.0M	—	43.7M	—	—
Debt	—	—	—	5.8M	—	2.0M	—	—
Equity	20.9M	71.3M	115.2M	458.4M	180.0%	—	—	—
Op CF	—	—	—	-138.1M	—	-174.7M	—	—
Inv CF	—	—	—	-323.2M	—	—	—	—
Fin CF	—	—	—	469.8M	—	—	—	—

Loading 1Y...

PRICE (1Y)-1.7%

SMA 50SMA 200

$13.78

RSI (14)

80.3

52W High

$40.43

From 52W High

0.3%

SCORE BREAKDOWN

Quality

ROIC

-36.5%21.0

ROE

-111.5%8.3

GP/Assets

—N/A

Op. Margin

0.0%38.1

FCF/Assets

-28.9%14.7

Piotroski

238.9

Int. Cover

—N/A

D/E Ratio

0.01x88.2

Current Ratio

16.52x94.4

Value

P/E (TTM)

—N/A

EV/EBITDA

-1.3x25.0

P/FCF

—N/A

P/B

1.8x67.4

P/S

—N/A

Div Yield

—N/A

Momentum

52W High %

34%9.5

RS 6M

-40%19.3

SMA 50/200

0.95x43.5

EPS Rev 4W

+10.3%89.5

EPS Rev 12W

+23.0%92.2

EPS Improve

+83%69.2

Q Growth

—N/A

FUNDAMENTALS

Market Cap

$584M

P/E (Forward)

-4.2x

Gross Margin

—

SECTOR PEERS

Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of MPLT are excluded.

Ticker	Company	Mkt Cap	StockRank	Signal
MPLT	MapLight Therapeutics, Inc.(you)	$584M	21	Sell
CBIO	Crescent Biopharma, Inc.	$659M	22	Sell
TECX	Tectonic Therapeutic, Inc.	$696M	21	Sell
DRUG	Bright Minds Biosciences Inc.	$714M	22	Sell
DNA	Ginkgo Bioworks Holdings, Inc.	$469M	20	Sell
ALT	Altimmune, Inc.	$605M	16	Strong Sell
RLMD	Relmada Therapeutics, Inc.	$462M	20	Sell
RZLT	Rezolute, Inc.	$445M	21	Sell
VSTM	Verastem, Inc.	$654M	26	Sell
ZURA	Zura Bio Limited	$548M	16	Strong Sell

Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.3%

MapLight Therapeutics, Inc. (MPLT): Stock Score Summary

MapLight Therapeutics, Inc. (MPLT) has a MoatMap StockRank of 21/100 based on Quality (34/100), Value (31/100), and Momentum (41/100) factor scores. The current signal is SELL.

Key Financial Metrics

Price	$13.78
Market Cap	$584M
P/E (Forward)	-4.18
Price/Book	1.80
Return on Equity	-111.5%
Return on Invested Capital	-36.5%
Debt/Equity	0.01x
Operating Margin	0.0%
Free Cash Flow	$-139M

MapLight Therapeutics, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).

Frequently Asked Questions

What is MapLight Therapeutics, Inc.’s (MPLT) StockRank?: MoatMap’s StockRank for MapLight Therapeutics, Inc. (MPLT) is 21/100, with a Sell signal. It is a composite of Quality (34), Value (31), and Momentum (41) factor ranks across MoatMap’s universe of 25,000+ stocks.
Does MapLight Therapeutics, Inc. have an economic moat?: MapLight Therapeutics, Inc. (MPLT) has a Quality factor score of 34/100. The Quality factor combines ROIC, Piotroski F-Score, and leverage: the financial fingerprints of a durable competitive advantage. A Quality score above 70 typically indicates a company with the characteristics of a moated business.
Is MapLight Therapeutics, Inc. a buy, hold, or sell?: MoatMap’s current signal for MapLight Therapeutics, Inc. (MPLT) is Sell, based on a StockRank of 21/100. Signals are derived mechanically from the StockRank composite and should be one input among many; combine with your own thesis on management, competitive position, and valuation.
What sector is MapLight Therapeutics, Inc. in?: MapLight Therapeutics, Inc. (MPLT) operates in the Healthcare sector, specifically the Biotechnology industry (United States).